Extrapolation between measures of symptom severity and change: An examination of the PANSS and CGI

Schizophrenia Research

Volumn 98, Issue 1-3, 2008, Pages 318-322

  Levine, Stephen Z ^a   Rabinowitz, Jonathan ^a   Engel, Rolf ^b   Etschel, Eva ^b   Leucht, Stefan ^c  

^a BAR ILAN UNIVERSITY   (Israel)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Schizophrenia; Severity of illness index; Treatment outcome

Indexed keywords

HALOPERIDOL; NEUROLEPTIC AGENT; PLACEBO; RISPERIDONE;

ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DISEASE SEVERITY; HUMAN; MAJOR CLINICAL STUDY; MENTAL DISEASE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; RATING SCALE; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCORING SYSTEM; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; FEASIBILITY STUDIES; HUMANS; META-ANALYSIS AS TOPIC; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMETRICS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGRESSION ANALYSIS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 36849032267     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2007.09.006     Document Type: Article

References (19)

1. Bernstein I.H., and Teng G. Factoring items and factoring scales are different: spurious evidence for multidimensionality due to item categorization. Psychol. Bull. 105 (1989) 467-477
2. Guy W.B. Manual for the ECDEU Assessment Battery. (2 edn) (1970), National Institute of Mental Health, Chevy Chase, Md
3. Jensen A.R., Saccuzzo D.P., and Larson G.E. Equating the advanced and standard forms of the Raven progressive matrices. Educ. Psychol. Meas. 48 (1988) 1091-1095
4. Kane J.M., Eerdekens M., Lindenmayer J.P., et al. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am. J. Psychiatry 160 (2003) 1125-1132
5. Kay S.R. Positive-negative symptom assessment in schizophrenia: psychometric issues and scale comparison. Psychiatr. Q. 61 (1990) 163-178
6. Kay S.R., Fiszbein A., and Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 13 (1987) 261-276
7. Kay S.R., Opler L.A., and Fiszbein A. The Positive and Negative Syndrome Scale (PANSS) Manual (2000), Multi-Health Systems Inc, Toronto, ON
8. Kay S.R., Opler L.A., and Lindenmayer J.P. The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation. Br. J. Psychiatry Suppl. (1989) 59-67
9. Kolen M.J., and Brennan R.L. Test Equating, Scaling, and Linking: Methods and Practices. (2 edn) (2004), Springer, NY
10. Leucht S., Kane J.M., Kissling W., et al. Clinical implications of Brief Psychiatric Rating Scale scores. Br. J. Psychiatry 187 (2005) 366-371
11. Leucht S., Kane J.M., Kissling W., et al. What does the PANSS mean?. Schizophr. Res. 79 (2005) 231-238
12. Leucht S., Kane J.M., Etschel E., et al. Linking the PANSS, BPRS, and CGI: clinical implications. Neuropsychopharmacology 31 (2006) 2318-2325
13. Marder S.R., and Meibach R.C. Risperidone in the treatment of schizophrenia. Am. J. Psychiatry 151 (1994) 825-835
14. Overall J.E., and Gorham D.R. The Brief Psychiatric Rating Scale. Psychol. Rep. 10 (1962) 790-812
15. Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group. Br. J. Psychiatry 166 (1995) 712-726 (discussion 727-733)
16. Rabinowitz J., and Ingham M. To what extent do the PANSS and CGI-S overlap?. National Institute of Mental Health (2005), Boca Raton, Florida
17. Rabinowitz J., Mehnert A., and Eerdekens M. To what extent do the PANSS and CGI-S overlap?. J. Clin. Psychopharmacol. 26 (2006) 303-307
18. Schooler N., Rabinowitz J., Davidson M., et al. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Am. J. Psychiatry 162 (2005) 947-953
19. Singh M.M., and Kay S.R. A comprehensive study of haloperidol and chlorpromazine in terms of clinical effects and therapeutic reversal with benztropine in schizophrenia: theoretical implications for potency differences among neuroleptics. Psychopharmacologia 43 (1975) 115-123